ストックスクリーナーアプリを入手
13.22
25.07%
2.65
前日終値:
$10.57
開ける：
$12.69
24時間の取引高:
70,377
Relative Volume:
0.81
時価総額：
$40.18M
収益：
$28.83M
当期純損益:
$-13.34M
株価収益率:
-8.6974
EPS:
-1.52
ネットキャッシュフロー:
$-7.49M
1週間 パフォーマンス:
+15.76%
1か月 パフォーマンス:
+31.02%
6か月 パフォーマンス:
+726.25%
1年 パフォーマンス:
+307.65%
1日の値動き範囲:
$11.29
$13.53
1週間の範囲:
$10.06
$13.53
52週間の値動き範囲:
$1.44
$36.00
Exicure Inc Stock (XCUR) Company Profile
XCUR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
0.1898 | 400.55M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.73 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.68 | 115.41M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
5.15 | 66.99M | 0 | 0 | 0 | 0.00 |
|
USTB
USAA Core Short-Term Bond ETF
|
50.53 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2020-12-18 | 開始されました | BMO Capital Markets | Outperform |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
Exicure Inc (XCUR) 最新ニュース
Exicure, Inc. Announces Issuance Of New Patent In Australia -March 13, 2025 at 05:39 pm EDT - Marketscreener.com
Exicure secures Australian patent for cancer treatment - Investing.com
Exicure announces issuance of new patent in Australia - TipRanks
Exicure's New Cancer Patent Breakthrough Powers Multiple Myeloma Clinical Trial - StockTitan
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Bluefield Daily Telegraph
Exicure announces board member departures, transitions By Investing.com - Investing.com Australia
(XCUR) Technical Pivots with Risk Controls - Stock Traders Daily
Exicure announces board member departures, transitions - Investing.com
Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 16.2% in February - Defense World
Where are the Opportunities in (XCUR) - Stock Traders Daily
Exicure (NASDAQ:XCUR) Stock Price Down 1.6% – Time to Sell? - Defense World
Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes - MSN
How To Trade (XCUR) - Stock Traders Daily
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - insights.citeline.com
How the (XCUR) price action is used to our Advantage - Stock Traders Daily
Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 17.3% in January - Defense World
Hitron Systems Inc. announced that it expects to receive KRW 30 billion in funding -September 05, 2024 - Marketscreener.com
Exicure Inc (XCUR) requires closer examination - US Post News
Exicure signs purchase agreement with GPCR Therapeutics - MSN
Exicure, back from brink and under new management, buys GPCR's US unit and clinical-stage drug - Fierce Biotech
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. - BioSpace
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. - Yahoo Finance
Exicure announces purchase agreement with GPCR Therapeutics - TipRanks
Exicure Acquires GPCR Therapeutics USA, Signs Major Licensing Deal for Drug Development - StockTitan
Exicure, Inc. (NASDAQ:XCUR) Sees Significant Decrease in Short Interest - Defense World
When (XCUR) Moves Investors should Listen - Stock Traders Daily
Exicure appoints new audit committee members By Investing.com - Investing.com Nigeria
Exicure Secures $8.7 Million in Stock Purchase Deal - MSN
Exicure appoints new audit committee members - Investing.com
Exicure, Inc. (NASDAQ:XCUR) Short Interest Update - Defense World
Exicure Stock Surges On Blood Cancer Portfolio Acquisition Plans, Regaining Nasdaq Compliance: Retail Exuberant - MSN
A Northwestern-born startup has new ownership — and a new focus - Crain's Chicago Business
Exicure Stock Surges On Blood Cancer Portfolio Acquisition Plans, Regaining Nasdaq Compliance: Retail Exuberan - Asianet Newsable
Exicure joins hands with GPCR Therapeutics for growth in biotech (NASDAQ:XCUR) - Seeking Alpha
Exicure signs MOU with GPCR Therapeutics - TipRanks
Exicure (XCUR) to Acquire GPCR USA, Gains Phase 2 Cancer Drug Pipeline with $2B Market Potential - StockTitan
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech - Yahoo Finance
CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes - Business Wire
Exicure Names Andy Yoo as President, CEO - MarketWatch
Exicure Shareholders Approve Major HiTron Equity Financing - TipRanks
Exicure, Inc. Appoints Andy Yoo as Chief Executive Officer - Marketscreener.com
Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive - EIN News
Exicure Secures $12M Strategic Investment as HiTron Systems Takes Majority Stake - StockTitan
Exicure (NASDAQ:XCUR) Unaudited Proforma Consolidated Balance Sheets Show Growth - Defense World
Exicure boosts equity, eyes Nasdaq compliance - Investing.com
Exicure Inc (XCUR) 財務データ
収益
当期純利益
現金流量
EPS
1.39%
0.55%
大文字化:
|
ボリューム (24 時間):